Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 4, 2005, Pages 329-333

  Tsai, James Y ^a   Iannitti, David ^a   Berkenblit, Anna ^b   Akerman, Paul ^a   Nadeem, Ahmed ^a   Rathore, Ritesh ^a   Harrington, David ^a   Roye, Dean ^a   Miner, Thomas ^a   Barnett, John M ^a   Maia, Christine ^a   Stuart, Keith ^b   Safran, Howard ^a,c  

^a Brown University Oncology Group   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MIRIAM HOSPITAL   (United States)

Author keywords

Cancer; Capecitabine; Carboplatin; Docetaxel; Esophageal; Gastric

Indexed keywords

AMINOTRANSFERASE; ANTIEMETIC AGENT; BILIRUBIN; CAPECITABINE; CARBOPLATIN; CREATININE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG HYPERSENSITIVITY; ESOPHAGUS CANCER; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; INFECTION; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; STOMACH CANCER; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; DEOXYCYTIDINE; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NAUSEA; NEUTROPENIA; STOMACH NEOPLASMS; TAXOIDS;

EID: 23244451584     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000158492.35639.92     Document Type: Article

References (20)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Ajani JA. Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol. 2000;18:4001-4003.
3. Tsai JY, Safran H. Status of treatment for advanced gastric carcinoma. Curr Oncol Rep. 2003;5:210-218.
4. Wils JA, Klein HO, Wagener DJ, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: a stop ahead in the treatment of advanced gastric cancer-a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol. 1991;9:827-831.
5. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol. 2000;18:2648-2657.
6. Kelsen DD, Atiq OT, Saltz L, et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol. 1992;10:541-548.
7. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15:261-267.
8. Ajani JA, Van Cutsem E, Moiseyenko V, et al. Docetaxel, cisplatin, and 5-fluorouracil compared to cisplatin and 5-fluorouracil for chemotherapy-naive patients with metastatic or locally recurrent unresectable gastric carcinoma (MGC). Interim results of a randomized phase III trial (V325) [abstract no. 999]. Proc Am Soc Clin Oncol. 2003;22:249.
9. Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol. 2000;18:1337-1345.
10. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274-1281.
11. Nadella P, Shapiro C, Otterson GA, et al. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol. 2002;20:2616-2623.
12. McDonald J, Smallery S, Benedetti J, et al. Chemoradiation after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-730.
13. De Gramont A, Boset JF, Milan C, et al. Randomized trial comparing monthly low dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancers: a French Intergroup Study. J Clin Oncol. 1997;15:808-815.
14. Findlay M, Cunningham D, Norman A, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol. 1994;5:609-616.
15. Kurosumi M, Tabei T, Suemasu K, et al. Enhancement of immunohistochemical reactivity of thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep. 2000;7: 945-948.
16. O'Shaughnessey J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812-2823.
17. Gadgeel SM, Shields AF, Heilbrun L, et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol. 2003;26:37-41.
18. Burris H. Weekly schedules of docetaxel. Semin Oncol. 1998;6(suppl 12):21-23.
19. Hainsworth JD, Burris HA, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol. 2001;19:3500-3505.
20. Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol. 2003;21:1307-1312.